Aescap Genetics heeft op het moment van schrijven 71% van het vermogen belegd in 18 ondernemingen.
Aescap Genetics Newsletter Q1 2022
At the time of writing, Aescap Genetics has invested 71% of its assets under management in 18 companies.
Aescap Life Sciences Nieuwsbrief Q1 2022
De NAV van het fonds daalde in de eerste helft van maart 6,8% en steeg vervolgens in de tweede helft met 10,8%. Het lijkt erop dat het sentiment voor biotech aandelen op zijn minst gestabiliseerd is. Het eerste kwartaal was een goede periode om nieuwe ondernemingen in de portfolio op te nemen.
Aescap Life Sciences Newsletter Q1 2022
The fund’s NAV fell 6.8% in the first half of March and then rose 10.8% in the second half. It seems that sentiment for biotech stocks has at least stabilized. The first quarter was a good period to include new companies in the portfolio.
Aescap Life Sciences Quarterly Update Q4 2021
The Year in Review and What is Coming Up.
Looking back at 2021 we saw sharp declining biotech share prices as of mid-February 2021 around the so-called ‘Turn out of Tech’.
Aescap Life Sciences Quarterly Update Q4 2021
The Year in Review and What is Coming Up.
Looking back at 2021 we saw sharp declining biotech share prices as of mid-February 2021 around the so-called ‘Turn out of Tech’.
Portfolio News – Acquisition of Portfolio Company Dicerna – Nov 18, 2021
Portfolio company Dicerna Pharmaceuticals announced that it has entered into a definitive agreement with pharma company Novo Nordisk under which Novo Nordisk will acquire Dicerna for $ 38,25 per share and a total equity value of $ 3,3 billion, representing an 80% premium compared to Dicerna’s share price at closing on Nov 17, 2021.
Portfolio News – Acquisition of Portfolio Company Dicerna – Nov 18, 2021
Portfolio company Dicerna Pharmaceuticals announced that it has entered into a definitive agreement with pharma company Novo Nordisk under which Novo Nordisk will acquire Dicerna for $ 38,25 per share and a total equity value of $ 3,3 billion, representing an 80% premium compared to Dicerna’s share price at closing on Nov 17, 2021.
Facts & Figures – From History to Future in Cancer Treatment
At the beginning of the 20th century, the only two options doctors had available to treat cancer were surgery and/or radiation therapy. At that time, cancers that couldn’t be removed or irradiated, because of their position or because they involved blood cells, were deemed untreatable.
Facts & Figures – From History to Future in Cancer Treatment
At the beginning of the 20th century, the only two options doctors had available to treat cancer were surgery and/or radiation therapy. At that time, cancers that couldn’t be removed or irradiated, because of their position or because they involved blood cells, were deemed untreatable.
